Teva Pharmaceutical Industries stock target raised to $50 by Argus
Published on 11/18/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst lifts Teva outlook
- Argus retained its Buy rating while raising its price target for Teva Pharmaceutical Industries.
- The analyst cited execution of Teva's Pivot to Growth strategy and recent pipeline progress.
- Argus expects earnings growth to resume next year after pressure from generic Revlimid and the Emalex acquisition.
On November 17, Markets Insider reported that Argus raised its price target for Teva Pharmaceutical Industries from 42 US dollars to 50 US dollars while retaining a Buy rating.
The analyst cited Teva's execution on the four pillars of its Pivot to Growth strategy. Argus said the company had entered the strategy's Accelerate Growth phase, according to the report.
Growth strategy supports rating
Argus also pointed to recent pipeline wins and Teva's execution as part of its investment view. The analyst expects earnings growth to resume next year, while Teva expects pressure on full-year 2026 earnings from generic Revlimid and the acquisition of Emalex.
Pipeline remains central
The higher target adds to a series of recent analyst actions following Teva's third-quarter results and its research and development update. The report frames pipeline development and the shift toward innovative medicines as central elements of the longer-term outlook.
Teva Pharmaceutical Industries
- Company: Teva Pharmaceutical Industries
- ISIN: US8816242098
- Ticker: TEVA
- Analyst: Argus
- Rating: Buy
- Price target: 50 US dollars
The S&P 500 provides the broader market backdrop for US-listed companies.
More news and analyses on Teva Pharmaceutical Industries stock
